Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Launched by OSCAR GERARDO ARRIETA RODRÍGUEZ · Dec 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying lung adenocarcinoma, a type of lung cancer, specifically in Mexican patients under the age of fifty. The main goal is to find out how common certain genetic changes, known as pathogenic variants, are in this group of patients. The researchers also want to understand how these genetic changes relate to the patients' health and the specific characteristics of their cancer. To participate, individuals must be at least 16 years old, have a confirmed diagnosis of lung adenocarcinoma, and meet certain family history or age-related criteria.

If you choose to take part in this study, you will need to provide a small blood sample after fasting overnight. This blood will be tested for genetic information that can help researchers learn more about lung adenocarcinoma. Participants should know that signing up requires informed consent, meaning you will be fully informed about the study and its procedures. The study is currently looking for volunteers, and your participation could help improve understanding and treatment of lung cancer for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Both sexes
• • ≥ 16 years old, according the institutional protocols for new patients admittances.
• • histologically confirmed lung adenocarcinoma (LUAD)
• • Signed written informed consent form
• • A life expectancy greater than 8 weeks.
• • Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET).
• Exclusion Criteria:
• • A sample of peripheral blood that is not accessible.
• • Insufficient clinical pathological information in the electronic clinical record.
• Elimination Criteria:
• • Withdrawal
• • Insufficient DNA quality and quantity for genomic sequencing analyses.
• • Lost of follow up